Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 19/20 | 0.49 |
| ▸ | ITGB7 | P26010 | 13/20 | 0.49 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3829634 | 0.95 | ITGB1 (0.49) | ITGB1ITGA4ITGB7ITGA5 | |
| SCHEMBL3831343 | 0.89 | ITGB1 (0.51) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL3835432 | 0.89 | ITGB1 (0.52) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL3831658 | 0.87 | L3MBTL1 (0.49) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL3837072 | 0.87 | ITGA4 (0.54) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL3833907 | 0.84 | ITGB1 (0.51) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL28778262 | 0.84 | ITGB1 (0.59) | ITGB1ITGA4ITGB7ITGA2 | |
| SCHEMBL3819749 | 0.84 | ITGB1 (0.59) | ITGB1ITGA4ITGB7ITGA2 | |
| SCHEMBL3830610 | 0.84 | ITGA4 (0.51) | ITGB1ITGA4ITGB7ITGA2ITGA5 | |
| SCHEMBL3838677 | 0.84 | NAMPT (0.52) | ITGB1ITGA4ITGB7ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091916-A2 | L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | AstraZeneca AB (SE) | 2009-08-26 | — | — | EP | claimed |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | claimed |
| WO-2007060408-A2 | L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | claimed |
| EP-2091916-A2 | L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | AstraZeneca AB (SE) | 2009-08-26 | — | — | EP | disclosed |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| WO-2007060408-A2 | L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137601-A1 | L-Phenylalanine Derivatives | ITGB5, ITGB1, ITGA2B | ITGB1 2/4885ITGA4 23/4885ITGB7 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.